Affiliations:
Louisiana State University Health Shreveport, Shreveport, LA, USA
Correspondence:
[*]
Address for correspondence: Siddharth Mahajan, MD, Department of Pediatrics, Divison of Cardiology, Louisiana State University Health Shreveport, 1501 Kings Hwy., Shreveport, LA, 71103. Tel.: +1 318 675 6429; E-mail: siddharth.mahajan@lsuhs.edu.
Abstract: A circular shunt is a poor prognostic factor associated with Ebstein’s anomaly. Targeting the constriction of the ductus arteriosus (DA) in order to limit or resolve the circular shunt, has been shown to improve fetal outcomes. Prenatal non-steroidal anti-inflammatory drugs (NSAIDs) have been known to constrict the DA. Recently, prenatal NSAIDs have been used for that purpose in the treatment of circular shunt. Limited research shows that it may be an effective treatment leading to improved fetal outcomes. In this article, we did an extensive review of literature to describe this therapy’s effectiveness and outcomes. 82% of fetuses were able to achieve ductal constriction with prenatal NSAID therapy. For fetuses who achieved ductal constriction, fetal demise was less likely (6%) when compared to those who were unable to achieve the same (50%). Of all the fetuses with hydrops, 50% had resoluation of hydrops with prenatal NSAID treatment.
